Frequently Asked Questions

Effective, convenient, and safe

Pentacel vaccine—the only DTaP-IPVa combination containing Hibb vaccine1

Pentacel vaccine can help protect in 4 doses (with a DTaP booster at 4-6 years of age).1,2,8-10

When you administer the Pentacel vaccine 4-dose series, you can help to provide effective protection, the convenience of a combination vaccine at 2, 4, 6, and 15-18 months of age, and safety you and parents can rely on.1

Children should receive a fifth dose of DTaP at 4-6 years of age.1

Help protect with Pentacel vaccine
Pentacel vaccine is the first pediatric pentavalent combination vaccine in the United States to contain the same 5 acellular pertussis antigens found in DAPTACEL®c vaccine.1

  • Pentacel and DAPTACEL vaccines contain the same pertussis antigens manufactured by the same process, but Pentacel vaccine contains twice as much inactivated PTd and 4 times as much FHAe as DAPTACEL vaccine1

May reduce the number of injections you give children and help enhance compliance
Pentacel vaccine contains a Hib component and fits easily into the primary series at 2, 4, and 6 months of age, with a booster at 15-18 months of age.2,3 It also helps you maximize shot savings within the first 2 years of life.2,3

Combination vaccines, like Pentacel vaccine, may enhance timeliness and compliance at the fourth dose.3,4
A 2012 National Immunization Survey showed that, by 24 months of age, 1 in 5 children did not receive all 4 recommended doses of DTaP vaccine.5 This leaves children at least 6 months behind the recommended immunization schedule and vulnerable to potentially devastating diseases.3

  • 1 in 5 children have not received their fourth dose of DTaP vaccine5
  • 1 in 5 children have not received their full series of Hib vaccine5
Image of chart: Drop-off in DTaP and Hib compliance nationwide

Rely on safety established in over 5000 infants
In clinical trials, fever and local and systemic reactions were reported at similar rates compared with separately administered DAPTACEL, ActHIB®i, and IPOL®j vaccines.1 Most cases of fever were mild to moderate.1

In clinical trials, the most common local and systemic adverse reactions to Pentacel vaccine included injection site redness, swelling, and tenderness; fever; fussiness; and crying.1

Pentacel vaccine safety was established in an ethnically diverse population of over 5000 infants 2 to 18 months of age.1

Over a decade of immunization experience
As of July 2014, more than 43 million doses of Pentacel vaccine have been distributed in North America.11

Take advantage of the benefits of Pentacel vaccine: immunogenicity, convenience, and safety. Add Pentacel vaccine to your immunization schedule today.

Learn more about Pentacel vaccine. Find all the details in the Pentacel vaccine Prescribing Information.

a DTaP = Diphtheria, tetanus, and acellular pertussis; IPV = Inactivated poliovirus.  b Hib = Haemophilus influenzae type b.  c Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.  d PT = Pertussis toxin detoxified.  e FHA = Filamentous hemagglutinin.  f Estimated vaccination coverage by 24 months of age.  g Primary Hib series = 2 or 3 doses.  h Full Hib series = 3 or 4 doses.  i Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate).  j Poliovirus Vaccine Inactivated.



Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).

Safety Information

The most common local and systemic adverse reactions to Pentacel vaccine include redness, swelling, and tenderness at the injection site; fever, fussiness, and abnormal crying. Other adverse reactions may occur. A known hypersensitivity (eg, anaphylaxis) to any component of Pentacel vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances are contraindications to vaccination.

The decision to give Pentacel vaccine should be based on careful consideration of the potential benefits and risks; if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; or if adverse events have occurred in temporal relation to a previous dose of Pentacel vaccine or receipt of any other tetanus toxoid, diphtheria toxoid, or pertussis antigen-containing vaccine. Apnea following intramuscular vaccination has been observed in some infants born prematurely. Encephalopathy within 7 days of administration of a previous dose of a pertussis antigen-containing vaccine or a progressive neurologic disorder is a contraindication. Vaccination with Pentacel vaccine may not protect all individuals.

Before administering Pentacel vaccine, please see accompanying full Prescribing Information.

Pentacel vaccine is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA and distributed by Sanofi Pasteur Inc.

Image of Send to a Friend
Image of Share This Page
Image of Print Page